Teva Pharmaceutical Industries (TEVA) Retained Earnings (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Retained Earnings across 18 years of filings, most recently posting -$2.5 billion for Q1 2026.

• Quarterly Retained Earnings rose 83.21% year-over-year to -$2.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.5 billion (up 83.21% YoY) and the FY2025 annual result came in at -$13.8 billion, down 337.17% from the prior year.
• Retained Earnings climbed to -$2.5 billion in Q1 2026, from -$13.8 billion in the prior quarter.
• Over five years, Retained Earnings peaked at -$287.0 million in Q1 2023 and troughed at -$15.0 billion in Q1 2025.
• A 5-year average of -$8.4 billion and a median of -$11.7 billion in 2022 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2023 — Retained Earnings jumped 87.44% — and 2024, when it sank 866.9%.
• Tracing TEVA's Retained Earnings over 5 years: stood at -$2.5 billion in 2022, then advanced by 5.17% to -$2.4 billion in 2023, then plunged by 32.05% to -$3.1 billion in 2024, then slumped by 337.17% to -$13.8 billion in 2025, then jumped by 81.75% to -$2.5 billion in 2026.
• Business Quant data shows TEVA's Retained Earnings at -$2.5 billion in Q1 2026, -$13.8 billion in Q4 2025, and -$14.2 billion in Q3 2025.